Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 15, Number 3—March 2009
Dispatch

Human Bocavirus and KI/WU Polyomaviruses in Pediatric Intensive Care Patients

Alma C. van de PolComments to Author , Tom F.W. Wolfs, Nicolaas J.G. Jansen, Jan L.L. Kimpen, Anton M. van Loon, and John W.A. Rossen
Author affiliations: University Medical Center Utrecht, Utrecht, the Netherlands (A.C. van de Pol, T.F.W. Wolfs, N.J.G. Jansen, J.L.L. Kimpen, A.M. van Loon, J.W.A Rossen); St. Elisabeth Hospital Tilburg, Tilburg, the Netherlands (J.W.A. Rossen)

Main Article

Table 2

Clinical characteristics of PICU patients with LRTIs and of PICU controls whose samples tested positive for HBoV, KIPyV, or WUPyV infections, the Netherlands, 2005–2008*

Patient no. Diagnosis Virus 
(Ct value) Sample type Sex Age, mo Immunocompromised Other underlying disease Length of stay, d Other viruses
LRTI group
1 LRTI HBoV (39.4) NPA F 13 No Pulmonary dysplasia (home mechanical ventilation) 10 Adeno, hMPV
2 LRTI HBoV (15.0) NPA F 9 No IRDS, PVL 10 Adeno
3 LRTI HBoV (16.6) NPA M 13 No Recurrent wheezing 5 RSV
4 LRTI HBoV (15.0) NPA F 19 No IRDS 7 None
5 LRTI WUPyV (19.6) NPA M 1 No None 11 RSV
6
LRTI
WUPyV (34.1)
NPA
F
41
No
Mitochondrial encephalopathy
18
Influenza
Control group
7 Sepsis HBoV (36.5) NPA F 27 No None 7 NA
8 Infectious meningitis HBoV (34.7) NPA F 100 No 22Q11 deletion (cardiac and neurologic disease) 3 NA
9 URTI HBoV (37.9) NPA M 41 No Spinal muscular atrophy 74 NA
10 Observation after brain biopsy HBoV/ KIPyV (32/39) NPA F 127 Yes AML, BMT, Brochiolitis obliterans 46 NA
11 VSD closure WUPyV (33.8) Throat swab F 15 No VSD 2 NA
12 Septic shock WUPyV (34.4) NPA M 40 No None 19 NA
13 Cardiac malformation KIPyV (34.1) NPA F 4 No Cardiac malformation 14 NA
14 Septic shock KIPyV (23.1) NPA M 152 Yes AML, aplasia 11 NA
15 ALTE KIPyV (26.7) NPA M 2 No None 8 NA

*PICU, Pediatric Intensive Care Unit, Wilhelmina Children’s Hospital, University Medical Center Utrecht, the Netherlands; LRTI, lower respiratory tract infection; HBoV, human bocavirus; KIPyV, KI polyomavirus; WUPyV, WU polyomavirus; Ct, cycle threshold; NPA, nasopharyngeal aspirate; Adeno, adenovirus; hMPV, human metapneumovirus; RSV, respiratory syncytial virus; IRDS, idiopathic respiratory distress syndrome; PVL, periventricular leukomalacia; NA, not assessed; URTI, upper respiratory tract infection; AML, acute myeloid leukemia; BMT, bone marrow transplant; VSD, ventricular septal defect; ALTE, apparent life-threatening event.

Main Article

Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external